Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

NCT05338580 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Company Development strategy adjustment

Conditions

First-line Non-small-cell Lung Cancer
First-line Urothelial Carcinoma
Second-line Urothelial Carcinoma
Second-line Melanoma

Interventions

DRUG: TJ271 Injection in Combination with Pembrolizumab

Sponsor

TJ Biopharma Co., Ltd.